Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sanai Health Industry Group Co's earnings before interest and taxes (EBIT) for the
six
months ended in Dec. 2025 was HK$-14.07 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-26.58 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Sanai Health Industry Group Co's annualizedROC % for the quarter that ended in Dec. 2025 was -13.69%.
Sanai Health Industry Group Co's annualizedROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -29.31%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
Sanai Health Industry Group Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 10.84%.
Sanai Health Industry Group Co (HKSE:01889) EBIT Explanation
1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Sanai Health Industry Group Co's annualizedROC % for the quarter that ended in Dec. 2025 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanai Health Industry Group Co EBIT Related Terms
Sanai Health Industry Group Co EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sanai Health Industry Group Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanai Health Industry Group Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sanai Health Industry Group Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Sanai Health Industry Group Co's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-26.58 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanai Health Industry Group Co (HKSE:01889) has a EBIT of HK$-26.58 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sanai Health Industry Group Co.
Is Sanai Health Industry Group Co's EBIT too high?
Sanai Health Industry Group Co's current EBIT is HK$-26.58 Mil. Overall, Sanai Health Industry Group Co has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sanai Health Industry Group Co's EBIT compare to ZTS and UTHR?
Sanai Health Industry Group Co's EBIT of HK$-26.58 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sanai Health Industry Group Co. Sanai Health Industry Group Co's current EBIT is HK$-26.58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanai Health Industry Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sanai Health Industry Group Co (HKSE:01889) is currently considered Possible Value Trap. The stock's GF Value™ is HK$0.42, compared to a current price of HK$0.19 — trading 53.8% below its estimated fair value. The current EBIT is HK$-26.58 Mil. Sanai Health Industry Group Co's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Sanai Health Industry Group Co (HKSE:01889), the current EBIT is HK$-26.58 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sanai Health Industry Group Co (HKSE:01889) Overvalued in 2026?
Based on GuruFocus' analysis, Sanai Health Industry Group Co stock appears to be undervalued.
The current stock price of HK$0.19 is trading 53.8% below its estimated GF Value™ of HK$0.42.
GuruFocus considers Sanai Health Industry Group Co to be Possible Value Trap.
Key valuation signals for HKSE:01889:
EBIT: HK$-26.58 Mil
GF Value™: HK$0.42 vs. price of HK$0.19 (53.8% below fair value)
No single metric tells the full story. See the HKSE:01889 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanai Health Industry Group Co Business Description
Sanai Health Industry Group Co Ltd is a pharmaceutical company. The company has three reportable segments namely Pharmaceutical products include development, manufacturing, marketing, and sales of pharmaceutical products and related software and provision of consultancy services. Finance leasing includes the provision of financial leasing services; Genetic testing and molecular diagnostic services segment. It generates maximum revenue from Pharmaceutical products segments. Geographically, it derives the majority of its revenue from the PRC.
40GF Score
Get the complete analysis for HKSE:01889
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01889 has been successfully added to your 
